108 related articles for article (PubMed ID: 31028607)
21. Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.
Breaux A; Turner B; Wu X; Rai SN; Riley EC; Mandadi M; Sanders MA
Clin Breast Cancer; 2019 Feb; 19(1):e261-e269. PubMed ID: 30509870
[TBL] [Abstract][Full Text] [Related]
22. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
[TBL] [Abstract][Full Text] [Related]
23. Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.
Spellman E; Sulayman N; Eggly S; Peshkin BN; Isaacs C; Schwartz MD; O'Neill SC
Psychooncology; 2013 Sep; 22(9):2110-6. PubMed ID: 23447452
[TBL] [Abstract][Full Text] [Related]
24. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Troester MA; Carey LA; Wheeler SB
Breast Cancer Res Treat; 2015 Aug; 153(1):191-200. PubMed ID: 26216535
[TBL] [Abstract][Full Text] [Related]
25. Physician's peer exposure and the adoption of a new cancer treatment modality.
Pollack CE; Soulos PR; Gross CP
Cancer; 2015 Aug; 121(16):2799-807. PubMed ID: 25903304
[TBL] [Abstract][Full Text] [Related]
26. Patient-Centered Communication for Discussing Oncotype DX Testing.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Wheeler SB
Cancer Invest; 2016 May; 34(5):205-12. PubMed ID: 27124287
[TBL] [Abstract][Full Text] [Related]
27. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
[TBL] [Abstract][Full Text] [Related]
28. A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning.
Kim I; Choi HJ; Ryu JM; Lee SK; Yu JH; Kim SW; Nam SJ; Lee JE
Eur J Surg Oncol; 2019 Feb; 45(2):134-140. PubMed ID: 30348602
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer.
Pollack CE; Soulos PR; Herrin J; Xu X; Christakis NA; Forman HP; Yu JB; Killelea BK; Wang SY; Gross CP
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376191
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
31. Knowledge about genomic recurrence risk testing among breast cancer survivors.
Lipkus IM; Vadaparampil ST; Jacobsen PB; Miree CA
J Cancer Educ; 2011 Dec; 26(4):664-9. PubMed ID: 21688183
[TBL] [Abstract][Full Text] [Related]
32. Adherence to guidelines in requesting Oncotype DX in a publicly funded health care system.
Martel S; Lambertini M; Simon R; Matte C; Prady C
Curr Oncol; 2018 Aug; 25(4):e311-e318. PubMed ID: 30111977
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Wang SY; Dang W; Richman I; Mougalian SS; Evans SB; Gross CP
J Clin Oncol; 2018 Jun; 36(16):1619-1627. PubMed ID: 29659329
[TBL] [Abstract][Full Text] [Related]
34. Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment.
Kozick Z; Hashmi A; Dove J; Hunsinger M; Arora T; Wild J; Shabahang M; Blansfield J
Am J Surg; 2018 Apr; 215(4):686-692. PubMed ID: 28606707
[TBL] [Abstract][Full Text] [Related]
35. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
de Boer RH; Baker C; Speakman D; Chao CY; Yoshizawa C; Mann GB
Med J Aust; 2013 Aug; 199(3):205-8. PubMed ID: 23909545
[TBL] [Abstract][Full Text] [Related]
36. [Clinicopathological features, prognosis and influence in the adjuvant treatment of the risk recurrence groups determined by the 21 gene expression profile, Oncotype Dx®, in early breast cancer].
Gerson Cwilich R; Alban de la Torre LF; Villalobos Prieto A; Serrano Olvera JA
Gac Med Mex; 2012; 148(2):117-24. PubMed ID: 22622310
[TBL] [Abstract][Full Text] [Related]
37. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
[TBL] [Abstract][Full Text] [Related]
38. Perioperative magnetic resonance imaging in breast cancer care: Distinct adoption trajectories among physician patient-sharing networks.
Xu X; Soulos PR; Herrin J; Wang SY; Pollack CE; Killelea BK; Forman HP; Gross CP
PLoS One; 2022; 17(3):e0265188. PubMed ID: 35290417
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of the Detection of Lymphovascular Invasion in Hormone Receptor-Positive Early Breast Cancer in the Era of Molecular Profiling.
Mutai R; Goldvaser H; Shochat T; Peretz I; Sulkes A; Yerushalmi R
Oncology; 2019; 96(1):14-24. PubMed ID: 30253418
[TBL] [Abstract][Full Text] [Related]
40. Women's experiences with genomic testing for breast cancer recurrence risk.
Tzeng JP; Mayer D; Richman AR; Lipkus I; Han PK; Valle CG; Carey LA; Brewer NT
Cancer; 2010 Apr; 116(8):1992-2000. PubMed ID: 20213682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
